Technology by Bilan Autumn 2020’s edition

Every two years, the well-known Swiss publication Bilan publishes the “Technology by Bilan” supplement. For this edition, Gilles Pfend, European & Swiss Patent Attorney and Partner at Katzarov, writes about the plausibility in patenting Life Sciences inventions.

“There is a risk when filing a patent application for an invention for which little or no experimental data exists. There is a substantial risk that this application, during its examination by the European Patent Office (EPO), will be objected to for lack of sufficiency or inventive step, through lack of plausibility or credibility.”

To find out more, please refer to the full article and multiple scenarios presented by Gilles Pfend or do not hesitate to contact us!

Fullscreen Mode